Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCM Lifescience CEO On Developing High Purity, Disease-Specific Stem Cell Therapies

Executive Summary

Emerging Company Profile: Capitalizing on its proprietary platform technologies designed to develop high efficacy, disease-specific and low cost stem cell products, South Korea's SCM Lifescience aims to prove in clinical trials how its product candidates differ from existing stem cell therapies.

You may also be interested in...



Korean Firms Join Hands To Pick Up Troubled US Cancer Vaccine Firm Argos

Argos Therapeutics lands in the hands of Genexine and SCM Lifescience after the US immunotherapy firm was put up for sale by the Delaware bankruptcy court. The Korean biotechs plan to use the company’s cGMP facilities and experience in large US Phase III trials to accelerate their global market entry.

Samsung Looks Beyond Biosimilars Via Takeda Tie-Up

Samsung Bioepis is shifting gears moving into the development of novel biologics via a strategic collaboration with Takeda. The partners will initially focus on acute pancreatitis and jointly develop Takeda's preclinical candidate in the segment.

Asia Deal Watch: Daiichi Sankyo Pays $200m To Ultragenyx For AAV Technology Access

A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context

Topics

Related Companies

UsernamePublicRestriction

Register

SC123726

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel